References

 

1.     Mattsson S, Johansson L, Leide Svegborn S, Liniecki J, Noßke D, Riklund KÅ, et al. ICRP Publication 128: Radiation Dose to Patients from Radiopharmaceuticals: a Compendium of Current Information Related to Frequently Used Substances. Ann ICRP 2015;44:7–321. https://doi.org/10.1177/0146645314558019.

2.     Munari M, Zucchetta P, Carollo C, Gallo F, De Nardin M, Marzola MC, et al. Confirmatory tests in the diagnosis of brain death: Comparison between SPECT and contrast angiography. Critical Care Medicine 2005;33:2068–2073. https://doi.org/10.1097/01.CCM.0000179143.19233.6A.

3.     Bonetti MG, Ciritella P, Valle G, Perrone E. 99mTc HM-PAO brain perfusion SPECT in brain death. Neuroradiology 1995;37:365–9.

4.     Facco E, Zucchetta P, Munari M, Baratto F, Behr A, Gregianin M, et al. 99mTc-HMPAO SPECT in the diagnosis of brain death. Intensive Care Medicine 1998;24:911–917.

5.     Banzo J, Razola P, Araíz JJ, Larraga J, Tardín L, Andrés A, et al. El estudio gammagráfico de perfusión cerebral como prueba de confirmación de muerte encefálica en el proceso de donación de órganos para trasplante. Revista Española de Medicina Nuclear e Imagen Molecular 2012;31:278–285. https://doi.org/10.1016/J.REMN.2012.03.013.

6.     Zaknun JJ, Bal C, Maes A, Tepmongkol S, Vazquez S, Dupont P, et al. Comparative analysis of MR imaging, Ictal SPECT and EEG in temporal lobe epilepsy: a prospective IAEA multi-center study. European Journal of Nuclear Medicine and Molecular Imaging 2008;35:107–115. https://doi.org/10.1007/s00259-007-0526-y.

7.     Patil S, Biassoni L, Borgwardt L. Nuclear Medicine in Pediatric Neurology and Neurosurgery: Epilepsy and Brain Tumors. Seminars in Nuclear Medicine 2007;37:357–381. https://doi.org/10.1053/j.semnuclmed.2007.04.002.

8.     Jones AL, Cascino GD. Evidence on Use of Neuroimaging for Surgical Treatment of Temporal Lobe Epilepsy. JAMA Neurology 2016;73:464. https://doi.org/10.1001/jamaneurol.2015.4996.

9.     Latchaw RE, Yonas H, Hunter GJ, Yuh WTC, Ueda T, Sorensen AG, et al. Guidelines and recommendations for perfusion imaging in cerebral ischemia: A scientific statement for healthcare professionals by the writing group on perfusion imaging, from the Council on Cardiovascular Radiology of the American Heart Association. Stroke 2003;34:1084–104. https://doi.org/10.1161/01.STR.0000064840.99271.9E.

10.     Bonte FJ, Weiner MF, Bigio EH, White CL. Brain blood flow in the dementias: SPECT with histopathologic correlation in 54 patients. Radiology 1997;202:793–797. https://doi.org/10.1148/radiology.202.3.9051035.

11.     Kapucu ÖL, Nobili F, Varrone A, Booij J, Vander Borght T, N\a agren K, et al. EANM procedure guideline for brain perfusion SPECT using 99m Tc-labelled radiopharmaceuticals, version 2 Background and definitions. Eur J Nucl Med Mol Imaging 2009. https://doi.org/10.1007/s00259-009-1266-y.

12.     Taïeb D, Hicks RJ, Hindié E, Guillet BA, Avram A, Ghedini P, et al. European Association of Nuclear Medicine Practice Guideline/Society of Nuclear Medicine and Molecular Imaging Procedure Standard 2019 for radionuclide imaging of phaeochromocytoma and paraganglioma. Eur J Nucl Med Mol Imaging 2019;46:2112–37. https://doi.org/10.1007/s00259-019-04398-1.

13.     O’Brien JT, Oertel WH, McKeith IG, Grosset DG, Walker Z, Tatsch K, et al. Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials. BMJ Open 2014;4:e005122. https://doi.org/10.1136/bmjopen-2014-005122.

14.     Seibyl JP, Kupsch A, Booij J, Grosset DG, Costa DC, Hauser RA, et al. Individual-Reader Diagnostic Performance and Between-Reader Agreement in Assessment of Subjects with Parkinsonian Syndrome or Dementia Using 123 I-Ioflupane Injection (DaTscan) Imaging n.d. https://doi.org/10.2967/jnumed.114.140228.

15.     Garnett ES, Firnau G, Nahmias C. Dopamine visualized in the basal ganglia of living man. Nature 1983;305:137–138. https://doi.org/10.1038/305137a0.

16.     Leenders KL, Palmer AJ, Quinn N, Clark JC, Firnau G, Garnett ES, et al. Brain dopamine metabolism in patients with Parkinson’s disease measured with positron emission tomography. Journal of Neurology, Neurosurgery, and Psychiatry 1986;49:853–60.

17.     Brooks DJ. The early diagnosis of Parkinson’s disease. Annals of Neurology 1998;44:S10–8.

18.     Ghaemi M, Hilker R, Rudolf J, Sobesky J, Heiss W-D. Differentiating multiple system atrophy from Parkinson’s disease: contribution of striatal and midbrain MRI volumetry and multi-tracer PET imaging. J Neurol Neurosurg Psychiatry 2002;73:517–523. https://doi.org/10.1136/jnnp.73.5.517.

19.     Heiss W-D, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson’s disease. European Journal of Neurology 2004;11:5–12.

20.     Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F]dopa PET findings in early Parkinson’s disease. Journal OfNeurology, Neurosurgery, and Psychiatry 1995;59:597–600. https://doi.org/10.1136/jnnp.59.6.597.

21.     Treglia G, Glaudemans AWJM, Bertagna F, Hazenberg BPC, Erba PA, Giubbini R, et al. Diagnostic accuracy of bone scintigraphy in the assessment of cardiac transthyretin-related amyloidosis: a bivariate meta-analysis. Eur J Nucl Med Mol Imaging 2018;45:1945–55. https://doi.org/10.1007/s00259-018-4013-4.

22.     Dorbala S, Ando Y, Bokhari S, Dispenzieri A, Falk RH, Ferrari VA, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 2 of 2-Diagnostic criteria and appropriate utilization. J Nucl Cardiol 2020;27:659–73. https://doi.org/10.1007/s12350-019-01761-5.

23.     Piccini P, Morrish PK, Turjanski N, Sawle GV, Burn DJ, Weeks RA, et al. Dopaminergic function in familial Parkinson’s disease: A clinical and18F-dopa positron emission tomography study. Annals of Neurology 1997;41:222–229. https://doi.org/10.1002/ana.410410213.

24.     Heiss W-D, Hilker R. The sensitivity of 18-fluorodopa positron emission tomography and magnetic resonance imaging in Parkinson’s disease. European Journal of Neurology 2004;11:5–12.

25.     Morbelli S, Esposito G, Arbizu J, Barthel H, Boellaard R, Bohnen NI, et al. EANM practice guideline/SNMMI procedure standard for dopaminergic imaging in Parkinsonian syndromes 1.0. Eur J Nucl Med Mol Imaging 2020;47:1885–912. https://doi.org/10.1007/s00259-020-04817-8.

26.     Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, Brendel M, Cecchin D, Ekmekcioglu O, Garibotto V, Lammertsma AA, Law I, Peñuelas I, Semah F, Traub-Weidinger T, van de Giessen E, Van Weehaeghe D, Morbelli S. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):632-651. doi: 10.1007/s00259-021-05603-w

27.     Verger A, Tolboom N, Cicone F, Chang SM, Furtner J, Galldiks N, Gempt J, Guedj E, Huang RY, Johnson DR, Law I, Le Rhun E, Short SC, Bent MJVD, Weehaeghe DV, Vogelbaum MA, Wen PY, Albert NL, Preusser M. Joint EANM/EANO/RANO/SNMMI practice guideline/procedure standard for PET imaging of brain metastases: version 1.0. Eur J Nucl Med Mol Imaging. 2025 Jan 7. doi: 10.1007/s00259-024-07038-5

28.     Verger A et al. Eur J Nucl Med Mol Imaging. 2025 Jan 7. doi: 10.1007/s00259-024-07038-5 

29.     Guedj et al. European Journal of Nuclear Medicine and Molecular Imaging (2022) 49:632–651

30.     Albert NL, Weller M, Suchorska B, Galldiks N, Soffietti R, Kim MM, et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. Neuro-Oncology 2016;18:1199–1208. https://doi.org/10.1093/neuonc/now058.

31.     Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol 2015;18:426–34. https://doi.org/10.1093/neuonc/nov148.

32.     Herholz K, Pietrzyk U, Voges J, Schröder R, Halber M, Treuer H, et al. Correlation of glucose consumption and tumor cell density in astrocytomas. Journal of Neurosurgery 1993;79:853–858. https://doi.org/10.3171/jns.1993.79.6.0853.

33.     Prieto E, Marti-Climent JM, Dominguez-Prado I, Garrastachu P, Diez-Valle R, Tejada S, et al. Voxel-Based Analysis of Dual-Time-Point 18F-FDG PET Images for Brain Tumor Identification and Delineation. Journal of Nuclear Medicine 2011;52:865–872. https://doi.org/10.2967/jnumed.110.085324.

34.     Hatzoglou V, Yang TJ, Omuro A, Gavrilovic I, Ulaner G, Rubel J, et al. A prospective trial of dynamic contrast-enhanced MRI perfusion and fluorine-18 FDG PET-CT in differentiating brain tumor progression from radiation injury after cranial irradiation. Neuro-Oncology 2016;18:873–880. https://doi.org/10.1093/neuonc/nov301.

35.     Spence AM, Muzi M, Mankoff DA, O’Sullivan SF, Link JM, Lewellen TK, et al. 18F-FDG PET of gliomas at delayed intervals: improved distinction between tumor and normal gray matter. Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine 2004;45:1653–9.

36.     Horky LL, Hsiao EM, Weiss SE, Drappatz J, Gerbaudo VH. Dual phase FDG-PET imaging of brain metastases provides superior assessment of recurrence versus post-treatment necrosis. Journal of Neuro-Oncology 2011;103:137–146. https://doi.org/10.1007/s11060-010-0365-8.

37.     Law I, Albert NL, Arbizu J, Boellaard R, Drzezga A, Galldiks N, et al. Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for imaging of gliomas using PET with radiolabelled amino acids and [18F]FDG: version 1.0. Eur J Nucl Med Mol Imaging 2019;46:540–57. https://doi.org/10.1007/s00259-018-4207-9.

38.     Rabinovici GD, Rosen HJ, Alkalay A, Kornak J, Furst AJ, Agarwal N, et al. Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD. Neurology 2011;77:2034–2042. https://doi.org/10.1212/WNL.0b013e31823b9c5e.

39.     Laforce R, Buteau JP, Paquet N, Verret L, Houde M, Bouchard RW. The Value of PET in Mild Cognitive Impairment, Typical and Atypical/Unclear Dementias: A Retrospective Memory Clinic Study. American Journal of Alzheimer’s Disease & Other Dementiasr 2010;25:324–332. https://doi.org/10.1177/1533317510363468.

40.     Morrish PK, Sawle GV, Brooks DJ. Clinical and [18F]dopa PET findings in early Parkinson’s disease. Journal OfNeurology, Neurosurgery, and Psychiatry 1995;59:597–600. https://doi.org/10.1136/jnnp.59.6.597.

41.     Kracht LW, Miletic H, Busch S, Jacobs AH, Voges J, Hoevels M, et al. Delineation of Brain Tumor Extent with [11C]L-Methionine Positron Emission Tomography: Local Comparison with Stereotactic Histopathology. Clinical Cancer Research 2004;10:7163–7170. https://doi.org/10.1158/1078-0432.CCR-04-0262.

42.    Pauleit D, Floeth F, Hamacher K, Riemenschneider MJ, Reifenberger G, Müller H-W, et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. Brain 2005;128:678–687. https://doi.org/10.1093/brain/awh399.

43.     Kratochwil C, Combs SE, Leotta K, Afshar-Oromieh A, Rieken S, Debus J, et al. Intra-individual comparison of 18F-FET and 18F-DOPA in PET imaging of recurrent brain tumors. Neuro-Oncology 2014;16:434–40. https://doi.org/10.1093/neuonc/not199.

44.     Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, et al. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research 2014;20:3550–9. https://doi.org/10.1158/1078-0432.CCR-13-1440.

45.     Galldiks N, Stoffels G, Filss C, Rapp M, Blau T, Tscherpel C, et al. The use of dynamic O-(2-18F-fluoroethyl)-l-tyrosine PET in the diagnosis of patients with progressive and recurrent glioma. Neuro-Oncology 2015;17:1293–300. https://doi.org/10.1093/neuonc/nov088.

46.     Cicone F, Minniti G, Romano A, Papa A, Scaringi C, Tavanti F, et al. Accuracy of F-DOPA PET and perfusion-MRI for differentiating radionecrotic from progressive brain metastases after radiosurgery. European Journal of Nuclear Medicine and Molecular Imaging 2015;42:103–111. https://doi.org/10.1007/s00259-014-2886-4.

47.     [Hutterer M, Nowosielski M, Putzer D, Jansen NL, Seiz M, Schocke M, et al. [18F]-fluoro-ethyl-l-tyrosine PET: a valuable diagnostic tool in neuro-oncology, but not all that glitters is glioma. Neuro-Oncology 2013;15:341–351. https://doi.org/10.1093/neuonc/nos300.

48.     Nobili F, Arbizu J, Bouwman F, Drzezga A, Agosta F, Nestor P, et al. European Association of Nuclear Medicine and European Academy of Neurology recommendations for the use of brain 18F-fluorodeoxyglucose positron emission tomography in neurodegenerative cognitive impairment and dementia: Delphi consensus. European Journal of Neurology 2018;25:1201–1217. https://doi.org/10.1111/ene.13728.

49.     Frisoni GB, Festari C, Massa F, Cotta Ramusino M, Orini S, Aarsland D, Agosta F, Babiloni C, Borroni B, Cappa SF, Frederiksen KS, Froelich L, Garibotto V, Haliassos A, Jessen F, Kamondi A, Kessels RP, Morbelli SD, O'Brien JT, Otto M, Perret-Liaudet A, Pizzini FB, Vandenbulcke M, Vanninen R, Verhey F, Vernooij MW, Yousry T, Boada Rovira M, Dubois B, Georges J, Hansson O, Ritchie CW, Scheltens P, van der Flier WM, Nobili F. European intersocietal recommendations for the biomarker-based diagnosis of neurocognitive disorders. Lancet Neurol. 2024 Mar;23(3):302-312. doi: 10.1016/S1474-4422(23)00447-7. PMID: 38365381.

50.      Traub-Weidinger T, Arbizu J, Barthel H, Boellaard R, Borgwardt L, Brendel M, Cecchin D, Chassoux F, Fraioli F, Garibotto V, Guedj E, Hammers A, Law I, Morbelli S, Tolboom N, Van Weehaeghe D, Verger A, Van Paesschen W, von Oertzen TJ, Zucchetta P, Semah F. EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy. Eur J Nucl Med Mol Imaging. 2024 Jun;51(7):1891-1908. doi: 10.1007/s00259-024-06656-3. Epub 2024 Feb 23. PMID: 38393374; PMCID: PMC11139752.

51.     Graus F, Titulaer MJ, Balu R, Benseler S, Bien CG, Cellucci T, et al. A clinical approach to diagnosis of autoimmune encephalitis. The Lancet Neurology 2016;15:391–404. https://doi.org/10.1016/S1474-4422(15)00401-9.

52.     Kamp, A., Andersson, M., Leide-Svegborn, S. et al. A revised compartmental model for biokinetics and dosimetry of 2-[18F]FDG. EJNMMI Phys 10, 10 (2023). https://doi.org/10.1186/s40658-023-00528-9

53.     Morbelli S, Zoccarato M, Bauckneht M, Anglani M, Cecchin D. 18F-FDG-PET and MRI in autoimmune encephalitis: a systematic review of brain findings. Clinical and Translational Imaging 2018:1–18. https://doi.org/10.1007/s40336-018-0275-x.

54.     Guedj E, Varrone A, Boellaard R, Albert NL, Barthel H, van Berckel B, Brendel M, Cecchin D, Ekmekcioglu O, Garibotto V, Lammertsma AA, Law I, Peñuelas I, Semah F, Traub-Weidinger T, van de Giessen E, Van Weehaeghe D, Morbelli S. EANM procedure guidelines for brain PET imaging using [18F]FDG, version 3. Eur J Nucl Med Mol Imaging. 2022 Jan;49(2):632-651. doi: 10.1007/s00259-021-05603-w. Epub 2021 Dec 9. Erratum in: Eur J Nucl Med Mol Imaging. 2022 May;49(6):2100-2101. doi: 10.1007/s00259-022-05755-3. PMID: 34882261; PMCID: PMC8803744.

55.     Minoshima S, Drzezga AE, Barthel H, Bohnen N, Djekidel M, Lewis DH, et al. SNMMI Procedure Standard/EANM Practice Guideline for Amyloid PET Imaging of the Brain 1.0 n.d. https://doi.org/10.2967/jnumed.116.174615.

56.      Rabinovici GD, Knopman DS, Arbizu J, Benzinger TLS, Donohoe KJ, Hansson O, et al. Updated appropriate use criteria for amyloid and tau PET: A report from the Alzheimer’s Association and Society for Nuclear Medicine and Molecular Imaging Workgroup. Alzheimer’s and Dementia. John Wiley and Sons Inc; 2025.

57.     Wolters EE, Papma JM, Verfaillie SCJ, Visser D, Weltings E, Groot C, et al. Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. Neurology. 2021;97:E1017–30.

58.     Golla SSV, Wolters EE, Timmers T, Ossenkoppele R, van der Weijden CWJ, Scheltens P, et al. Parametric methods for [18F]flortaucipir PET. Journal of Cerebral Blood Flow and Metabolism. 2020;40:365–73.

59.     Altomare D, Caprioglio C, Assal F, Allali G, Mendes A, Ribaldi F, et al. Diagnostic value of amyloid-PET and tau-PET: a head-to-head comparison. Eur J Nucl Med Mol Imaging. 2021;48:2200–11.

60.     Tian M, Civelek AC, Carrio I, Watanabe Y, Kang KW, Murakami K, et al. International consensus on the use of tau PET imaging agent 18F-flortaucipir in Alzheimer’s disease. Eur J Nucl Med Mol Imaging. 2022;49:895–904.

61.     USF and DA 2020. FDA. Tauvid Integrated Review Document. FDA website. . https://www.fda.gov/media/140343/download.

62.     Groot C, Villeneuve S, Smith R, Hansson O, Ossenkoppele R. Tau PET Imaging in Neurodegenerative Disorders. Journal of Nuclear Medicine. 2022;63:20S-26S.

63.     Boccalini C, Ribaldi F, Hristovska I, Arnone A, Peretti DE, Mu L, et al. The impact of tau deposition and hypometabolism on cognitive impairment and longitudinal cognitive decline. Alzheimer’s and Dementia. 2024;20:221–33.

64.     Ossenkoppele R, Smith R, Mattsson-Carlgren N, Groot C, Leuzy A, Strandberg O, et al. Accuracy of Tau Positron Emission Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-Head Comparison against Amyloid Positron Emission Tomography and Magnetic Resonance Imaging. JAMA Neurol. 2021;78:961–71.

65.     Groot C, Smith R, Collij LE, Mastenbroek SE, Stomrud E, Binette AP, et al. Tau Positron Emission Tomography for Predicting Dementia in Individuals With Mild Cognitive Impairment. JAMA Neurol. 2024;81:845–56.

66.     Ossenkoppele R, Hansson O. Towards clinical application of tau PET tracers for diagnosing dementia due to Alzheimer’s disease. Alzheimer’s and Dementia. 2021;17:1998–2008.

67.     Fleisher AS, Pontecorvo MJ, Devous MD, Lu M, Arora AK, Truocchio SP, et al. Positron Emission Tomography Imaging with [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes. JAMA Neurol. 2020;77:829–39.

68.     Mathoux G, Boccalini C, Peretti DE, Arnone A, Ribaldi F, Scheffler M, et al. A comparison of visual assessment and semi-quantification for the diagnostic and prognostic use of [18F]flortaucipir PET in a memory clinic cohort. Eur J Nucl Med Mol Imaging. 2024;51:1639–50.

69.     Villemagne VL, Leuzy A, Bohorquez SS, Bullich S, Shimada H, Rowe CC, et al. CenTauR: Toward a universal scale and masks for standardizing tau imaging studies. Alzheimers Dement (Amst). 2023;15:e12454.

70.     Leuzy A, Raket LL, Villemagne VL, Klein G, Tonietto M, Olafson E, et al. Harmonizing tau positron emission tomography in Alzheimer’s disease: The CenTauR scale and the joint propagation model. Alzheimer’s and Dementia. 2024; 

71.     Tran-Gia, J., Eberlein, U., Lassmann, M. et al. Analysis of image data from the EuroNet PHL-C2 trial indicates a potential reduction in injected F-18 FDG activities in children: a proposal to update the EANM Paediatric Dosage Card. Eur J Nucl Med Mol Imaging 51, 405–411 (2024). https://doi.org/10.1007/s00259-023-06396-w

72.     Kamp, A., Andersson, M., Leide-Svegborn, S. et al. A revised compartmental model for biokinetics and dosimetry of 2-[18F]FDG. EJNMMI Phys 10, 10 (2023). https://doi.org/10.1186/s40658-023-00528-9